285 related articles for article (PubMed ID: 17015625)
21. Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis.
Pantel A; Petrella S; Veziris N; Matrat S; Bouige A; Ferrand H; Sougakoff W; Mayer C; Aubry A
J Antimicrob Chemother; 2016 Sep; 71(9):2428-31. PubMed ID: 27234461
[TBL] [Abstract][Full Text] [Related]
22. WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis.
Ouchi Y; Mukai T; Koide K; Yamaguchi T; Park JH; Kim H; Yokoyama K; Tamaru A; Gordon SV; Nakajima C; Suzuki Y
Tuberculosis (Edinb); 2020 Jan; 120():101891. PubMed ID: 31778929
[TBL] [Abstract][Full Text] [Related]
23. Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR.
van Doorn HR; An DD; de Jong MD; Lan NT; Hoa DV; Quy HT; Chau NV; Duy PM; Tho DQ; Chinh NT; Farrar JJ; Caws M
Int J Tuberc Lung Dis; 2008 Jul; 12(7):736-42. PubMed ID: 18544197
[TBL] [Abstract][Full Text] [Related]
24. The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis.
Mayer C; Takiff H
Microbiol Spectr; 2014 Aug; 2(4):MGM2-0009-2013. PubMed ID: 26104201
[TBL] [Abstract][Full Text] [Related]
25. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.
Wang JY; Lee LN; Lai HC; Wang SK; Jan IS; Yu CJ; Hsueh PR; Yang PC
J Antimicrob Chemother; 2007 May; 59(5):860-5. PubMed ID: 17412727
[TBL] [Abstract][Full Text] [Related]
26. Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones.
Matrat S; Aubry A; Mayer C; Jarlier V; Cambau E
Antimicrob Agents Chemother; 2008 Aug; 52(8):2909-14. PubMed ID: 18426901
[TBL] [Abstract][Full Text] [Related]
27. Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74.
Lau RW; Ho PL; Kao RY; Yew WW; Lau TC; Cheng VC; Yuen KY; Tsui SK; Chen X; Yam WC
Antimicrob Agents Chemother; 2011 Feb; 55(2):608-14. PubMed ID: 20956608
[TBL] [Abstract][Full Text] [Related]
28. Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis.
Luo T; Yuan J; Peng X; Yang G; Mi Y; Sun C; Wang C; Zhang C; Bao L
J Antimicrob Chemother; 2017 Jul; 72(7):1893-1900. PubMed ID: 28387828
[TBL] [Abstract][Full Text] [Related]
29. Functional Characterization of the DNA Gyrases in Fluoroquinolone-Resistant Mutants of Francisella novicida.
Caspar Y; Siebert C; Sutera V; Villers C; Aubry A; Mayer C; Maurin M; Renesto P
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167561
[TBL] [Abstract][Full Text] [Related]
30. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review.
Avalos E; Catanzaro D; Catanzaro A; Ganiats T; Brodine S; Alcaraz J; Rodwell T
PLoS One; 2015; 10(3):e0120470. PubMed ID: 25816236
[TBL] [Abstract][Full Text] [Related]
31. [Induction in vitro and stability of Mycobacterium tuberculosis resistance to ofloxacin].
Yang H; Hu Z; Sha W; Lu J; Cui Z; Wang J; Huang X; Xiao H
Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Apr; 48(4):318-23. PubMed ID: 24969458
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of binding of fluoroquinolones to the quinolone resistance-determining region of DNA gyrase: towards an understanding of the molecular basis of quinolone resistance.
Madurga S; Sánchez-Céspedes J; Belda I; Vila J; Giralt E
Chembiochem; 2008 Sep; 9(13):2081-6. PubMed ID: 18677735
[TBL] [Abstract][Full Text] [Related]
33. Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations.
Kambli P; Ajbani K; Nikam C; Khillari A; Shetty A; Udwadia Z; Georghiou SB; Rodwell TC; Catanzaro A; Rodrigues C
Int J Tuberc Lung Dis; 2015 Oct; 19(10):1227-9. PubMed ID: 26459538
[TBL] [Abstract][Full Text] [Related]
34. Biochemistry. Protein that mimics DNA helps tuberculosis bacteria resist antibiotics.
Ferber D
Science; 2005 Jun; 308(5727):1393. PubMed ID: 15933168
[No Abstract] [Full Text] [Related]
35. Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutations.
McGrath M; Gey van Pittius NC; Sirgel FA; Van Helden PD; Warren RM
Antimicrob Agents Chemother; 2014 May; 58(5):2912-5. PubMed ID: 24514091
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.
Niward K; Ängeby K; Chryssanthou E; Paues J; Bruchfeld J; Jureen P; Giske CG; Kahlmeter G; Schön T
J Antimicrob Chemother; 2016 Feb; 71(2):333-8. PubMed ID: 26538509
[TBL] [Abstract][Full Text] [Related]
37. Genotypic detection of fluoroquinolone resistance in drug-resistant Mycobacterium tuberculosis at a tertiary care centre in south Coastal Karnataka, India.
Chawla K; Kumar A; Shenoy VP; Chakrabarty S; Satyamoorthy K
J Glob Antimicrob Resist; 2018 Jun; 13():250-253. PubMed ID: 29421317
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
Gomez C; Ponien P; Serradji N; Lamouri A; Pantel A; Capton E; Jarlier V; Anquetin G; Aubry A
Bioorg Med Chem; 2013 Feb; 21(4):948-56. PubMed ID: 23294829
[TBL] [Abstract][Full Text] [Related]
39. Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.
Kambli P; Ajbani K; Sadani M; Nikam C; Shetty A; Udwadia Z; Rodwell TC; Catanzaro A; Rodrigues C
Tuberculosis (Edinb); 2015 Mar; 95(2):137-41. PubMed ID: 25522842
[TBL] [Abstract][Full Text] [Related]
40. Some Synonymous and Nonsynonymous
Ajileye A; Alvarez N; Merker M; Walker TM; Akter S; Brown K; Moradigaravand D; Schön T; Andres S; Schleusener V; Omar SV; Coll F; Huang H; Diel R; Ismail N; Parkhill J; de Jong BC; Peto TE; Crook DW; Niemann S; Robledo J; Smith EG; Peacock SJ; Köser CU
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
